Literature DB >> 23991291

Afatinib as first-line treatment for patients with advanced non-small-cell lung cancer harboring EGFR mutations: focus on LUX-Lung 3 and LUX-Lung 6 phase III trials.

Antonio Passaro1, Bruno Gori, Filippo de Marinis.   

Abstract

Entities:  

Keywords:  Non-small-cell lung cancer (NSCLC); afatinib; epithelial growth factor receptor (EGFR); tyrosine kinase inhibitor (TKI)

Year:  2013        PMID： 23991291      PMCID： PMC3755655          DOI： 10.3978/j.issn.2072-1439.2013.07.32

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  7 in total

1.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

2.  First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.

Authors:  Ji-Youn Han; Keunchil Park; Sang-We Kim; Dae Ho Lee; Hyae Young Kim; Heung Tae Kim; Myung Ju Ahn; Tak Yun; Jin Seok Ahn; Cheolwon Suh; Jung-Shin Lee; Sung Jin Yoon; Jong Hee Han; Jae Won Lee; Sook Jung Jo; Jin Soo Lee
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

3.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

Authors:  Tetsuya Mitsudomi; Satoshi Morita; Yasushi Yatabe; Shunichi Negoro; Isamu Okamoto; Junji Tsurutani; Takashi Seto; Miyako Satouchi; Hirohito Tada; Tomonori Hirashima; Kazuhiro Asami; Nobuyuki Katakami; Minoru Takada; Hiroshige Yoshioka; Kazuhiko Shibata; Shinzoh Kudoh; Eiji Shimizu; Hiroshi Saito; Shinichi Toyooka; Kazuhiko Nakagawa; Masahiro Fukuoka
Journal:  Lancet Oncol       Date:  2009-12-18       Impact factor: 41.316

4.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

Authors:  Caicun Zhou; Yi-Long Wu; Gongyan Chen; Jifeng Feng; Xiao-Qing Liu; Changli Wang; Shucai Zhang; Jie Wang; Songwen Zhou; Shengxiang Ren; Shun Lu; Li Zhang; Chengping Hu; Chunhong Hu; Yi Luo; Lei Chen; Ming Ye; Jianan Huang; Xiuyi Zhi; Yiping Zhang; Qingyu Xiu; Jun Ma; Li Zhang; Changxuan You
Journal:  Lancet Oncol       Date:  2011-07-23       Impact factor: 41.316

5.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

6.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Authors:  Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

7.  Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.

Authors:  James Chih-Hsin Yang; Vera Hirsh; Martin Schuler; Nobuyuki Yamamoto; Kenneth J O'Byrne; Tony S K Mok; Victoria Zazulina; Mehdi Shahidi; Juliane Lungershausen; Dan Massey; Michael Palmer; Lecia V Sequist
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544
  7 in total
  6 in total

1.  Prolonged survival with erlotinib followed by afatinib in a caucasian smoker with metastatic, poorly differentiated large cell carcinoma of the lung: a case report.

Authors:  María Ángeles Sala González
Journal:  Cancer Biol Ther       Date:  2015-07-17       Impact factor: 4.742

2.  Cytotoxicity of allitinib, an irreversible anti-EGFR agent, in a large panel of human cancer-derived cell lines: KRAS mutation status as a predictive biomarker.

Authors:  Renato José Silva-Oliveira; Viviane Aline Oliveira Silva; Olga Martinho; Adriana Cruvinel-Carloni; Matias Eliseo Melendez; Marcela Nunes Rosa; Flávia Escremim de Paula; Luciano de Souza Viana; André Lopes Carvalho; Rui Manuel Reis
Journal:  Cell Oncol (Dordr)       Date:  2016-02-26       Impact factor: 6.730

Review 3.  Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) - Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy.

Authors:  Qamar Ghafoor; Shobhit Baijal; Phillipe Taniere; Brendan O'Sullivan; Matthew Evans; Gary Middleton
Journal:  Pathol Oncol Res       Date:  2017-12-21       Impact factor: 3.201

4.  Lentiviral vector-mediated RBM5 overexpression downregulates EGFR expression in human non-small cell lung cancer cells.

Authors:  Zhenzhong Su; Jinzhi Yin; Lijing Zhao; Ranwei Li; Hong Liang; Jie Zhang; Ke Wang
Journal:  World J Surg Oncol       Date:  2014-12-02       Impact factor: 2.754

Review 5.  [Current Status and Progress in Molecular Imaging of Non-small Cell Lung 
Cancer for Molecular Targeted EGFR-TKI Treatment Sensitivity and 
Treatment Tolerance Prediction].

Authors:  Dong Dai; Wengui Xu; Qi Wang; Xiaofeng Li; Yanjia Zhu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2017-12-20

6.  Long-lasting response to afatinib that persisted after treatment discontinuation in a case of EGFR-mutated lung adenocarcinoma.

Authors:  Yumie Yamanaka; Yoshitaka Seki; Takeo Ishikawa; Kazuyoshi Kuwano
Journal:  BMJ Case Rep       Date:  2019-01-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.